McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Can Retail Pharmacy USA Aid Walgreen Boots' (WBA) Q2 Earnings?
by Zacks Equity Research
Solid prescription volume growth and brand inflation anticipated to have aided Walgreen Boots' (WBA) Retail Pharmacy USA performance in Q2.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to gain traction from its multi-year strategic growth initiative and distribution solutions segment.
Is McKesson (MCK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
MCK vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MCK vs. COO: Which Stock Is the Better Value Option?
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MCK) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for McKesson (MCK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to McKesson (MCK) stock based on the movements in the options market lately.
Is McKesson (MCK) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is McKesson (MCK) Up 0.1% Since Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MCK or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. WST: Which Stock Is the Better Value Option?
Why McKesson (MCK) Could Be a Top Value Stock Pick
by Zacks Equity Research
McKesson (MCK) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health
by Zacks Equity Research
Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health
4 Finest Value Stocks Based on Discounted PEG
by Urmimala Biswas
A lower PEG ratio, preferably less than 1, indicates both undervaluation and solid future growth potential of a stock.
Zacks.com featured highlights include: DaVita, Legg Mason, PG&E, Cardinal Health and McKesson
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, Legg Mason, PG&E, Cardinal Health and McKesson
McKesson Corporation Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor McKesson Corporation
5 Great GARP Stocks Based on Discounted PEG
by Urmimala Biswas
PEG-based investing can be more rewarding with the addition of a few other relevant parameters.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
5 Stocks to Watch as Fatalities Due to Coronavirus Rise
by Zacks Equity Research
Coronavirus is ravaging China and several other countries. With no cure yet, health officials are struggling to stop its spread. Demand for medical supplies like masks is up manifold.
Company News for Feb 5, 2020
by Zacks Equity Research
Companies In The News Are: RCL, RL, SPG, MCK.
McKesson (MCK) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty Solutions, Medical-Surgical Solutions and Other segments.
McKesson (MCK) Tops Q3 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 7.63% and -0.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Earnings Season Could Be Great for McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Uber (UBER) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Higher ridesharing revenues are likely to have boosted Uber's (UBER) top line in fourth-quarter 2019.
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.